-
Prorenoate potassium
- names:
potassium 3-((4aS,4bS,6aS,7R,9aS,9bR,9cS,10aR)-7-hydroxy-4a,6a-dimethyl-2-oxo-2,3,4,4a,4b,5,6,6a,7,8,9,9a,9b,9c,10,10a-hexadecahydrocyclopenta[a]cyclopropa[l]phenanthren-7-yl)propanoate
- CAS号:
49847-97-4
MDL Number: - MF(分子式): C23H31KO4 MW(分子量): 410.59
- EINECS: Reaxys Number:
- Pubchem ID: Brand:BIOFOUNT
| 货品编码 | 规格 | 纯度 | 价格 (¥) | 现价(¥) | 特价(¥) | 库存描述 | 数量 | 总计 (¥) |
|---|
| 中文别名 | potassium 3-((4aS,4bS,6aS,7R,9aS,9bR,9cS,10aR)-7-hydroxy-4a,6a-dimethyl-2-oxo-2,3,4,4a,4b,5,6,6a,7,8,9,9a,9b,9c,10,10a-hexadecahydrocyclopenta[a]cyclopropa[l]phenanthren-7-yl)propanoate |
| 英文别名 | Prorenoate potassium; Sc 23992; Sc-23992; Sc23992; |
| CAS号 | 49847-97-4 |
| Inchi | InChI=1S/C23H32O4.K/c1-21-7-3-13(24)11-18(21)14-12-15(14)20-16(21)4-8-22(2)17(20)5-9-23(22,27)10-6-19(25)26;/h11,14-17,20,27H,3-10,12H2,1-2H3,(H,25,26);/q;+1/p-1/t14-,15-,16+,17+,20-,21+,22+,23-;/m1./s1 |
| InchiKey | NLSAMWIBIQWHTK-TZHLAWPMSA-M |
| 分子式 Formula | C23H31KO4 |
| 分子量 Molecular Weight | 410.59 |
| 溶解度Solubility | |
| 性状 | Solid powder |
| 储藏条件 Storage conditions | Dry, dark and store at 0-4℃ for short term (days to weeks) or -20℃ for long term (Store correctly 2-3years). |
| 产品说明 | Prorenoate potassium(CAS:49847-97-4):仅限应用于工业或者科学研究过程中非医疗目的,不应用于人类或动物的临床诊断以及治过程疗,该产品非药用,非食用。 |
| Introduction | Prorenoate potassium is is a synthetic steroidal antimineralocorticoid. |
| Application1 | |
| Application2 | |
| Application3 |
| [1]McInnes GT, Shelton JR, Harrison IR, Perkins RM, Palmer RF. Comparison of prorenoate potassium and spironolactone after repeated doses and steady state plasma levels of active metabolites. Br J Clin Pharmacol. 1982 Feb;13(2):187-94. PubMed PMID: 7059416; PubMed Central PMCID: PMC1401979. |
| [2]McInnes GT, Harrison IR, Shelton JR, Perkins RM, Clarke JM. Relative potency of prorenoate potassium and spironolactone in attenuating diuretic induced hypokalaemia. Br J Clin Pharmacol. 1984 Aug;18(2):169-74. PubMed PMID: 6487456; PubMed Central PMCID: PMC1463509. |
| [3] Levine D, Ramsay L, Auty R, Branch R, Tidd M. Antagonism of endogenous mineralocorticoids in normal subjects by prorenoate potassium and spironolactone. Eur J Clin Pharmacol. 1976 Mar 22;09(5-6):381-6. PubMed PMID: 786663. |
| [4] Ramsay LE, Shelton JR, Tidd MJ. The pharmacodynamics of single doses of prorenoate potasssium and spironolactone in fludrocortisone treated normal subjects. Br J Clin Pharmacol. 1976 Jun;3(3):475-82. PubMed PMID: 788750; PubMed Central PMCID: PMC2958760. |
| [5] Ramsay L, Harrison I, Shelton J, Tidd M. Relative potency of prorenoate and spironolactone in normal man. Clin Pharmacol Ther. 1975 Oct;18(4):391-400. PubMed PMID: 1100306. |
6: McInnes GT, Shelton JR, Harrison IR. Steady-state relative potency of aldosterone antagonists: spironolactone and prorenoate. Clin Pharmacol Ther. 1981 May;29(5):679-86. PubMed PMID: 7214797.7: Lumb GD, Rust JH. The pathologic response of the liver and thyroid of the rat to potassium prorenoate (SC-23992). Toxicol Pathol. 1985;13(4):315-24. PubMed PMID: 3834584.8: Netchitailo P, Delarue C, Perroteau I, Jegou S, Tonon MC, Leroux P, Leboulenger F, Kusmierek MC, Capron MH, Vaudry H. Effect of aldosterone antagonists on mineralocorticoid synthesis in vitro. Inhibition of aldosterone production by prorenoate-K. Eur J Pharmacol. 1982 Feb 5;77(4):243-9. PubMed PMID: 6277668.9: Auty R, Branch RA, Cole EN, Levine D, Ramsay L. Prolactin, diuretics and urinary electrolytes in normal subjects. J Endocrinol. 1976 Aug;70(2):173-81. PubMed PMID: 965879.10: McInnes GT, Shelton JR, Ramsay LE, Harrison IR, Asbury MJ, Clarke JM, Perkins RM, Venning GR. Relative potency and structure activity relationships of aldosterone antagonists in healthy man: correlation with animal experience. Br J Clin Pharmacol. 1982 Mar;13(3):331-9. PubMed PMID: 6460516; PubMed Central PMCID: PMC1402118.1
对不起,暂无产品评价!
MSDS
SDS 1.0 中文
展开
SDS 1.0 英文
展开
- 相关产品
-
< >
- 推荐产品
-
< >
- 最新产品
-
< >
新闻
抱歉,暂无数据!


购物车 


